Hepatocellular carcinoma after direct‐acting antivirals for hepatitis C is associated with KIR‐HLA types predicting weak NK cell‐mediated immunity

• Published in: European journal of immunology Vol. 54; no. 8; pp. e2350678 - n/a
• Main Authors: Ryan, James C., Haight, Christina, Niemi, Erene C., Grab, Joshua D., Dodge, Jennifer L., Lanier, Lewis L., Monto, Alexander
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.08.2024
• Subjects: Adult; Aged; Antiviral Agents; Antiviral Agents - therapeutic use; Antiviral drugs; Carcinoma; Carcinoma, Hepatocellular - immunology; Cirrhosis; Complementation; Female; Follow-Up Studies; Hepacivirus - immunology; Hepatitis C; Hepatitis C - complications; Hepatitis C - drug therapy; Hepatitis C - immunology; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - immunology; Hepatocellular; Hepatocellular carcinoma; HLA Antigens - immunology; Humans; Immunity; Immunity, Cellular; Innate; Killer cell immunoglobulin-like receptors; Killer Cells; Killer Cells, Natural - immunology; Liver cancer; Liver cirrhosis; Liver Neoplasms - immunology; Male; Middle Aged; Natural; Natural killer cells; Receptors, KIR - immunology; Tissue typing; Hepatocellular; Carcinoma; Killer Cells; Antiviral Agents; Innate; Hepatitis C; Natural; Immunity

Background and aims Second‐generation direct‐acting antivirals (2G DAA) to cure HCV have led to dramatic clinical improvements. HCV‐associated hepatocellular carcinoma (HCC), however, remains common. Impaired immune tumor surveillance may play a role in HCC development. Our cohort evaluated the effe...